FDA
-
-
-
-
-
-
-
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
-
-
-
-
-
-
-
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
-
-
-
-
-
-
-
Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
-
-
-
-
-
-
-
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
-
-
-
-
-
-
-
Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
-
-
-
-
-
-
-
ACURX regains nasdaq compliance with bid price and equity rules
-
-
-
-
-
-
-
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./
-
330,724 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All
